» Articles » PMID: 33369474

Matrix Metalloproteinase-11 Gene Polymorphisms As a Risk for Hepatocellular Carcinoma Development in Egyptian Patients

Overview
Specialty Oncology
Date 2020 Dec 28
PMID 33369474
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic hepatitis C (CHC) virus infection is one of major risk factors of hepatocellular carcinoma (HCC) in Egypt, which is a major cause of cancer mortalityin the world. Matrix metalloproteinase-11 (MMP-11) has an important role in tumor migration and metastasis. Therefore, this study aimed to determine relation between MMP-11 gene polymorphisms and risk of HCC development among Egyptian cirrhotic patients.

Subjects And Methods: Two hundred and sixty patients were included, 140 of them with HCC on top of CHC and 120 patients with post CHC liver cirrhosis (LC) as well as 140 subjects were enrolled in the study as healthy controls. Two single nucleotide polymorphisms (SNPs) rs738791 and rs738792 for MMP-11 gene were done using real-time PCR.

Results: Combination of CT and TT allele of rs738791 genotypes was more significantly frequent in HCC compared to LC patients and controls, however, a higher frequency of T allele was found in HCC patients compared to LC and controls. In spite of lake of significant difference between patient groups regarding the rs738792 genotypes, the CC genotype was considered a risk of developing portal vein thrombosis, and was associated with advanced tumor stage, increased tumor size, higher Cancer of the Liver Italian Program [CLIP] score, more advanced Barcelona stage [D] and with child Pugh class [C].

Conclusion: Genetic variations in MMP-11 may be implicated in post HCV-HCC development and might be dependable biomarkers for HCC progression.

Citing Articles

Exploring Hepatocellular Carcinoma Pathogenesis: The Influence of Genetic Polymorphisms.

Mollazadeh S, Saeedi N, Al-Asady A, Ghorbani E, Khazaei M, Ryzhikov M Curr Pharm Des. 2024; 31(6):432-442.

PMID: 39297458 DOI: 10.2174/0113816128327773240827062719.


Evaluation of Circular RNA SMARCA5 as a Novel Biomarker for Hepatocellular Carcinoma.

Bedair H, El-Banna E, Ahmed E, Elhelbawy M, Abdelfattah A, Khalaf F Asian Pac J Cancer Prev. 2024; 25(4):1411-1417.

PMID: 38680002 PMC: 11162735. DOI: 10.31557/APJCP.2024.25.4.1411.


Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease.

Sosna B, Aebisher D, Mysliwiec A, Dynarowicz K, Bartusik-Aebisher D, Oles P Int J Mol Sci. 2024; 25(1).

PMID: 38203373 PMC: 10779120. DOI: 10.3390/ijms25010202.


The Impact of Matrix Metalloproteinase-11 Polymorphisms on Colorectal Cancer Progression and Clinicopathological Characteristics.

Huang H, Shiu B, Su S, Huang C, Ting W, Chang L Diagnostics (Basel). 2022; 12(7).

PMID: 35885589 PMC: 9317823. DOI: 10.3390/diagnostics12071685.

References
1.
Gupta H, Youn G, Shin M, Suk K . Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019; 7(5). PMC: 6560397. DOI: 10.3390/microorganisms7050121. View

2.
Zhu K, Dai Z, Zhou J . Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy. Biomark Res. 2013; 1(1):10. PMC: 4177612. DOI: 10.1186/2050-7771-1-10. View

3.
Di Bisceglie A . Pretransplant treatments for hepatocellular carcinoma: do they improve outcomes?. Liver Transpl. 2005; (11 Suppl 2):S10-3. DOI: 10.1002/lt.20598. View

4.
Geervliet E, Bansal R . Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases. Cells. 2020; 9(5). PMC: 7290342. DOI: 10.3390/cells9051212. View

5.
Bi Q, Tang S, Xia L, Du R, Fan R, Gao L . Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One. 2012; 7(6):e40169. PMC: 3387011. DOI: 10.1371/journal.pone.0040169. View